ClinicalTrials.gg
CompletedNCT00283751Updated Jan 27, 2017

Comparison of Insulin Detemir or Insulin Glargine as Add on to Oral Antidiabetic Drugs in Type 2 Diabetes

A Phase 3 interventional study of insulin detemir and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 96 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-27.

Primary conditionDiabetes Mellitus, Type 2Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 2
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 2, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
583
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 — 1 open to participants now, 1 under way, none of them phase 3. Insulin Detemir · Diabetes Mellitus, Type 2.

Enrollment
5th of 43
583 · median 130
Started
2003
with 4 others
Phase 3
12 of 43
none open now
Registered
8th of 43
by date
Lead sponsor
28 of 43
Novo Nordisk A/S

Among the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is one of 5 that started in 2003, is one of 12 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2 is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Detemir

Insulin Detemir: first FDA approval 2005 (LEVEMIR FLEXTOUCH), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing Insulin Detemir in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This trial is conducted in Europe and the United States of America (USA). The aim of the trial is to test if Insulin Detemir as add-on to current Oral Antidiabetic Drug treatment is at least as effective as Insulin Glargine as add-on to current Oral Antidiabetic Drug treatment in reducing HbA1c in patients with Type 2 Diabetes.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 2

Browse trials for

04

In context

Diabetes Mellitus, Type 2 Reclassified

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

This study's enrollment of 583 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.

Browse Diabetes Mellitus, Type 2 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes for more than 12 months, and no previous insulin treatment
  • Oral Antidiabetic Drug treatment for at least 4 months
  • (BMI) less than 40 kg/m2
  • 7.5-10.0%

Exclusion criteria

Exclusion Criteria:

  • Current or previous treatment with thiazolidinediones within the last 6 months
  • Oral Antidiabetic Drug treatment with combination of three or more Oral Antidiabetic Drugs within the last 6 months
  • Proliferative retinopathy or maculopathy
  • Known hypoglycaemia unawareness
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
583 participants (actual)

Interventions

07

What researchers measure

Primary outcomes

  1. HbA1c

    Time frame: after 52 weeks

Secondary outcomes

  1. Insulin antibodies

  2. Incident of hypoglycaemic episodes and adverse events

  3. Plasma glucose profiles

  4. Change in body weight

08

Study locations

96 sites
  • Novo Nordisk Investigational Site
    Greenbrae, California 94904, United States
  • Novo Nordisk Investigational Site
    La Mesa, California 91942, United States
  • Novo Nordisk Investigational Site
    West Palm Beach, Florida 33401, United States
  • Novo Nordisk Investigational Site
    Atlanta, Georgia 30318, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60607, United States
  • Novo Nordisk Investigational Site
    Springfield, Illinois 62711, United States
  • Novo Nordisk Investigational Site
    Topeka, Kansas 66606, United States
  • Novo Nordisk Investigational Site
    Chesterfield, Missouri 63017, United States
  • Novo Nordisk Investigational Site
    St. Louis, Missouri 63141, United States
  • Novo Nordisk Investigational Site
    Lincoln, Nebraska 68521, United States
  • Novo Nordisk Investigational Site
    Pleasantville, New Jersey 08232, United States
  • Novo Nordisk Investigational Site
    Cleveland, Ohio 44195, United States
  • Novo Nordisk Investigational Site
    Kettering, Ohio 45429, United States
  • Novo Nordisk Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Novo Nordisk Investigational Site
    Mt. Pleasant, South Carolina 29464, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75230, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75246, United States
  • Novo Nordisk Investigational Site
    Dallas, Texas 75390-8858, United States
  • Novo Nordisk Investigational Site
    San Antonio, Texas 78229, United States
  • Novo Nordisk Investigational Site
    Warrenton, Virginia 20186, United States
  • Novo Nordisk Investigational Site
    Seattle, Washington 98105, United States
  • Novo Nordisk Investigational Site
    Ebreichsdorf, 2483, Austria
  • Novo Nordisk Investigational Site
    Gratwein, 8112, Austria
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Neunkirchen, 2620, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, A 1160, Austria
  • Novo Nordisk Investigational Site
    Wolfsberg, 9400, Austria
  • Novo Nordisk Investigational Site
    Bonheiden, 2820, Belgium
  • Novo Nordisk Investigational Site
    Brussels, 1090, Belgium
  • Novo Nordisk Investigational Site
    Edegem, 2650, Belgium
  • Novo Nordisk Investigational Site
    Gent, 9000, Belgium
  • Novo Nordisk Investigational Site
    Leuven, 3000, Belgium
  • Novo Nordisk Investigational Site
    Besancon, 25030, France
  • Novo Nordisk Investigational Site
    Bondy, 93143, France
  • Novo Nordisk Investigational Site
    Grenoble, 38043, France
  • Novo Nordisk Investigational Site
    LA ROCHELLE cedex, 17019, France
  • Novo Nordisk Investigational Site
    Lyon, 69437, France
  • Novo Nordisk Investigational Site
    Nantes, 44093, France
  • Novo Nordisk Investigational Site
    Narbonne, 11108, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Paris Cedex 10, 75475, France
  • Novo Nordisk Investigational Site
    Paris, 75877, France
  • Novo Nordisk Investigational Site
    Poitiers, 86000, France
  • Novo Nordisk Investigational Site
    Strasbourg, 67091, France
  • Novo Nordisk Investigational Site
    TOULOUSE cedex, 31054, France
  • Novo Nordisk Investigational Site
    Bad Kreuznach, 55545, Germany
  • Novo Nordisk Investigational Site
    Bad Mergentheim, 97980, Germany
  • Novo Nordisk Investigational Site
    Bad Neuenahr-Ahrweiler, 53474, Germany
  • Novo Nordisk Investigational Site
    Berlin, 13355, Germany
  • Novo Nordisk Investigational Site
    Dresden, 01307, Germany
  • Novo Nordisk Investigational Site
    Flensburg, 24939, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Freiburg, 79106, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Furth, 93437, Germany
  • Novo Nordisk Investigational Site
    Genthin, 39307, Germany
  • Novo Nordisk Investigational Site
    Giessen, 35390, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20251, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 21073, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 22607, Germany
  • Novo Nordisk Investigational Site
    Heidelberg, 69115, Germany
  • Novo Nordisk Investigational Site
    Krefeld, 47798, Germany
  • Novo Nordisk Investigational Site
    Ludwigshafen, 67059, Germany
  • Novo Nordisk Investigational Site
    Marl, 45770, Germany
  • Novo Nordisk Investigational Site
    München, 81925, Germany
  • Novo Nordisk Investigational Site
    Neumünster, 24534, Germany
  • Novo Nordisk Investigational Site
    Neuss, 41460, Germany
  • Novo Nordisk Investigational Site
    Nürnberg, 90402, Germany
  • Novo Nordisk Investigational Site
    Rehlingen-Siersburg, 66780, Germany
  • Novo Nordisk Investigational Site
    Saarbrücken, 66121, Germany
  • Novo Nordisk Investigational Site
    Schaafheim, 64850, Germany
  • Novo Nordisk Investigational Site
    Schwabenheim, 55270, Germany
  • Novo Nordisk Investigational Site
    Schwedt, 16303, Germany
  • Novo Nordisk Investigational Site
    St. Ingbert, 66386, Germany
  • Novo Nordisk Investigational Site
    Völklingen, 66333, Germany
  • Novo Nordisk Investigational Site
    Würzburg, 97072, Germany
  • Novo Nordisk Investigational Site
    Dublin, DUBLIN 8, Ireland
  • Novo Nordisk Investigational Site
    Dublin, Ireland
  • Novo Nordisk Investigational Site
    Ayr, KA6 6DX, United Kingdom
  • Novo Nordisk Investigational Site
    Barnsley, S75 2EP, United Kingdom
  • Novo Nordisk Investigational Site
    Bolton, BL1 4QS, United Kingdom
  • Novo Nordisk Investigational Site
    Bradford, BD9 6RJ, United Kingdom
  • Novo Nordisk Investigational Site
    Church Village, CF38 1AB, United Kingdom
  • Novo Nordisk Investigational Site
    Cosham, PO6 3LY, United Kingdom
  • Novo Nordisk Investigational Site
    Dundee, DD1 9SY, United Kingdom
  • Novo Nordisk Investigational Site
    Glasgow, G42 9TY, United Kingdom
  • Novo Nordisk Investigational Site
    Harrow, HA1 3UJ, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE5 4PW, United Kingdom
  • Novo Nordisk Investigational Site
    Livingstone, EH54 6PP, United Kingdom
  • Novo Nordisk Investigational Site
    London, SE5 9RS, United Kingdom
  • Novo Nordisk Investigational Site
    Newcastle, NE7 7DN, United Kingdom
  • Novo Nordisk Investigational Site
    Poole, BH15 2JB, United Kingdom
  • Novo Nordisk Investigational Site
    Salford, M6 8HD, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
09

References and documents

Publications

  • Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia. 2008 Mar;51(3):408-16. doi: 10.1007/s00125-007-0911-x. Epub 2008 Jan 16. PubMed 18204830 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2003, a primary completion of Nov 2004 and a completion of Nov 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2006
First posted
Jan 30, 2006
Start
Mar 2003
Primary completionActual
Nov 2004
CompletionActual
Nov 2004
Last update
Jan 27, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00283751
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jan 30, 2006
Start date
Mar 2003
Primary completion
Nov 2004
Completion
Nov 2004
Last update
Jan 27, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin Detemir · Insulin Glargine

Start the discussion